0 Items
Select Page

Usutu Virus

The first human case of Usutu viral infection was identified in the Central African Republic in 1981. The first human cases to be documented in Europe, were in Italy in 2009. These European cases were also the first to exhibit neurological manifestation of the disease, as the only two previous cases in Africa exhibited fever, rash, and jaundice. This relatively unknown and emerging zoonotic virus highlights the importance of vector-borne disease surveillance for human health.

At The Native Antigen Company, we have developed recombinant Usutu NS1 proteins to support research into the disease and development of specific immunoassays.

Usutu Virus Background

Usutu virus (USUV) is an enveloped, positive-sense, single-stranded RNA virus that belongs to the genus Flavivirus. USUV is a member of the Japanese encephalitis sero-complex of the family Flaviridae and is related to West Nile virus. The Usutu virus is maintained in a cycle between birds, which are regarded as the primary reservoir and amplification host, in addition to ornithophilic mosquitoes. USUV has also been reported to infect humans, horses and bats, which act as incidental hosts (Ashraf, U. et al). Usutu virus is recognised as an emerging pathogen and has recently been isolated from the mosquito species, C. pipiens, raising concerns that the mosquito species may act as a bridge vector, enabling transmission of USUV to mammals (Pauli, G et al).

USUV was first identified in South Africa in 1959, but later emerged in Austria in 2001, spreading throughout Europe and the Asian continent to infect a wide variety of bird species. In Europe, circulating USUV causes severe neurological symptoms in birds and is responsible for significant numbers of deaths in bird populations, including blackbirds and great grey owls. Although USUV is recognised as an emerging pathogen, little is known about USUV pathogenesis in humans. Cases of human USUV infection are uncommon but significant neurological disorders, such as encephalitis and meningoencephalitis have been reported in immunocompromised and immunocompetent patients infected with USUV (Salinas, S. et al).

References

  1. Ashraf, U et al (2015). Usutu Virus: An Emerging Flavivirus in Europe. Viruses. 7: 219–238.
  2. Pauli, G et al (2014). Usutu Virus. Transfus. Med. Hemother. 41: 73–82.
  3. Salinas, S et al (2017). Deleterious effect of Usutu virus on human neural cells. PLoS Negl. Trop Dis. 11: e0005913.

Usutu Antigens

The Native Antigen Company prepare recombinant Usutu virus NS1 protein in a proprietary mammalian cell expression system, to generate highly pure NS1 protein in its glycosylated and predominantly hexameric form.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Overcoming Zika-Dengue cross-reactivity: the highly specific immunoassays your lab needs

In the global battle against Zika virus, serological cross-reactivity with Dengue is a major challenge for academics, epidemiologists and pharmaceutical companies alike. Novel immunoassays can now overcome this problem and could prove a real game-changer in Zika...

The Right Tools for Rubella

Rubella remains a significant pathogen worldwide, with 100,000 cases of congenital rubella syndrome estimated to occur every year. Vaccines to rubella are highly safe and have effectively eliminated endemic infection in many developed countries, yet inadequate...

Visualising viral infection with immunofluorescence microscopy

Following the latest immunofluoresence data for our Zika and Dengue antibodies, we’ve invited VRS to write a short blog one of their areas of expertise: The applications of immunofluorescence microscopy in studying viruses.   A lot of what we know about biology...

Challenges to Effective Yellow Fever Diagnostics

Yellow fever is a haemorrhagic viral disease, transmitted by infected mosquitos in Africa and South America. While an effective vaccine is available, inadequate vaccination of endemic areas has made diagnostics a necessity to controlling ongoing outbreaks. However,...

Five Methods You Can Use to Overcome Zika-Dengue Cross-Reactivity

Cross-reactivity between the Zika and Dengue viruses in serological assays is one of the biggest challenges faced by the epidemiologists, academics and pharmaceutical companies trying to control the Zika epidemic, as it brings the quality and reliability of diagnostic...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

4 + 1 =

Live Customer Feedback